TwitterYouTubeLinkedInEmail

Personalis Earns Top Spot in The Scientist’s Top 10 Innovations of 2022

Translational Research

23 Jan, 2017

Comprehensive Tumor Characterization for Immuno Oncology, Clinical Trials, and Cancer Research

GenomeWeb: Comprehensive Tumor Characterization for Immuno Oncology, Clinical Trials, and Cancer Research This GenomeWeb seminar outlines a targeted enrichment technology to improve next-generation sequencing assays for cancer research and clinical applications. Presenters: Richard Chen, MD and Michael James Clark, PhD More Info: NGS is increasingly being used to support cancer clinical trials, translational [...]

Read More
7 Dec, 2016

Tumor Characterization Solutions for Clinical Trials, Cancer Research & Immuno-Oncology

Tumor Characterization Solutions for Clinical Trials, Cancer Research & Immuno-Oncology This presentation covers comprehensive tumor characterization solutions for clinical trials, cancer research and immune-oncology, including: specific challenges in sequencing and analyzing tumors for neoantigen identification; key differentiators of the ACE ImmunoID as compared to standard NGS offerings; and a review of the technical [...]

Read More
26 Sep, 2016

Find the answers to the most complex biological questions, with augmented NGS

Find the answers to the most complex biological questions, with augmented NGS Find the answers to the most complex biological questions, with augmented NGS Finding the answers to complex biological questions, requires a deeper understanding of cancer biology. Personalis ACE Cancer Exome and ACE Cancer Transcriptome features augmented DNA and RNA sequencing for [...]

Read More

Personalizing Precision Oncology.

©2023 Personalis, Inc. All rights reserved. All trademarks are the property of Personalis, Inc. or their respective owners. All products described here are for Research Use Only and not for use in diagnostic procedures (except as specifically noted).
Go to Top